繁
简
Market+ (iPhone)
Market+ (Android)
Mobile Site
US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
Quote Service
Market
Market
Quotes
Quotes
Analysis
Analysis
Commentary
Commentary
Warrants&CBBCs
Warrants&CBBCs
Warrants&CBBCs Overview
Warrants
CBBCs
ETF
ETF
MPF
MPF
Education
Members
Members
About Us
About Us

IPO Plus - IPO

To-be Listed
Name▼
/
Code▼
 Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date▼
Listing Date▲
REFIRE
02570.HK		 Electrical Components & Equipment 145-165 20 3,333 2024/12/03 2024/12/05 2024/12/06
Dmall
02586.HK		 Application Software 30.21 100 N/A 2024/12/03 2024/12/05 2024/12/06
Mao Geping
01318.HK		 Beauty & Toiletries Products and Services 26.3-29.8 100 3,010 2024/12/05 2024/12/09 2024/12/10
RAINMED-B (02297.HK)
Summary
Founded in 2014, we are a China-based medical device company, with our current focus on the design, development and commercialization of coronary angiography-derived fractional flow reserve system (“caFFR System”) and coronary angiography-derived index of microvascular resistance system (“caIMR System”). Our Core Products, caFFR System and caIMR System, are innovative medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (“CAD”). They are designed to eliminate the usage of pressure wires, significantly reduce the risk of technical errors and operation time, and improve physiological assessment. These two systems are currently utilized singularly for precision diagnosis of CAD. As fractional flow reserve (“FFR”) measures the macro- circulation of arteries which account for 5% of all arteries and index of microcirculatory resistance (“IMR”) measures the micro-circulation of arteries which account for 95% of all arteries, therefore, using a combination of IMR and FFR can provide a comprehensive evaluation on coronary circulation status of CAD patients. These two systems are expected to form the center and crucial modules for our future vascular interventional surgical robots.

Our caFFR System has obtained both certificates of CE Mark in Europe and NMPA approval in China. With the high accuracy rate of over 95% and convenient operation process that takes less than five minutes, our caFFR System has become a leading domestic FFR measurement product and is currently competing closely with an international leading medical device company for the national leader position in FFR measurement market in China, according to CIC. We plan to expand the indication of our caFFR System from the current scope (covering patients with stable angina pectoris, unstable angina pectoris and post-acute phase of myocardial infarction) to further cover patients experiencing acute ST segment elevation myocardial infarction (“STEMI”), acute Non-ST segment elevation myocardial infarction (“NSTEMI”) and heart failure with preserved ejection fraction (“HFpEF”). In addition, we are also developing our caIMR System, which is the only less-invasive IMR measurement product having completed a confirmatory clinical trial globally and is expected to become the first less-invasive IMR system approved for commercialization globally, according to CIC. Building on our caFFR System and caIMR System, we aim to launch our vascular interventional surgical robot, a one-stop hybrid procedure, that can be carried out for diagnostic and therapeutic purposes by connecting and integrating all our clinical applications, to automate the whole process of percutaneous coronary intervention (“PCI”) by 2024.

WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP AND/OR MARKET OUR CAFFR SYSTEM AND CAIMR SYSTEM, INCLUDING THE EXPANSION OF THE INDICATION OF OUR CAFFR SYSTEM.

We are deeply rooted in precision diagnosis for CAD in China, which is an underpenetrated market. Among all the precision diagnostic methods, FFR, a physiological functional parameter, is an important precision diagnosis measurement to assess the functional significance of coronary artery stenosis that is strongly recommended by multiple authorities globally, including the European Society of Cardiology and the Chinese Society of Cardiology, to guide PCI together with coronary angiography (“CAG”). Despite the high prevalence of CAD and the benefits of precision diagnostic methods, however, the penetration rate of FFR is rather low, leaving the market underpenetrated. According to CIC, in 2020, the number of FFR measurement procedures performed per million CAD patients was approximately 800, and the penetration rate of FFR measurement procedures among all patients receiving CAG was 0.4% in China, as compared to approximately 16,300 and 22.5% in the U.S., respectively. This low penetration rate in China is expected to reach 22.5% in 2030, according to CIC. One particular reason for the current low penetration of FFR measurement in China is the inefficiency and complexity of the conventional pressure wire-based approach. According to CIC, each Chinese cardiologist performs approximately four times the number of CAG each day as compared to U.S. cardiologists, and the conventional FFR measurement, which takes 15-30 minutes to complete, significantly limits Chinese cardiologists’ capability to perform time-consuming wire-based diagnosis procedures. In comparison, FFR measurement can be completed within five minutes using our caFFR System, at a high accuracy rate of over 95%. When calculating accuracy rates, the results of wire-free measurement (including FFR) are compared with the results of wire-based measurement, which is considered as the reference measurement standard with a theoretical 100% accuracy rate given it remains the gold standard in guiding the decision to proceed with PCI.

IMR is a quantitative method to assess the microvascular function of blood vessels, and is used to identify effective adjunctive treatment to reduce microcirculatory dysfunction and improve future prognosis after PCI. According to CIC, up to 70% of patients receiving CAG have microvascular dysfunction, and thus are in need of IMR measurement. However, it has been impossible to obtain a precise measurement of IMR without invasive procedures thus far, which makes IMR measurement time-consuming and unstable due to the complexity of the operation. Our caIMR System is an innovative and less-invasive product that is designed to address these shortcomings in the diagnosis of microcirculation disorders. It achieved a high evaluation accuracy of 84.2% in the feasibility clinical trial and 93.8% in the confirmatory clinical trial. Our caIMR System can significantly reduce the measurement time of IMR and diagnosis of coronary microvascular diseases (“CMVD”) to less than five minutes on average compared with 40-60 minutes in wire-based IMR measurements.



Source: Rainmed Medical-B (02297) Prospectus (IPO Date : 2022/06/27)
Listing Market MAIN
Industry Biotechnology - Medical Devices
Background Others
Major Business Area N/A
Corporate Information
Substantial Shareholders Huo Yunfei (18.52%)
Huo Yunlong (13.73%)
[02318] Ping An Insurance (Group) Company Of China Limited (10.28%)
Shanghai Tongxiang Haoqian Enterprise Management Partnership (8.58%)
Zhou Bin & Associates (6.97%)
Liu Jingxia & Associates (5.12%)
Shanghai Jingmairun Enterprise Management Center (L.P.) (5.05%)
Directors Huo Yunfei (Chairman and Chief Executive Officer and Executive Director)
Gu Yang (Vice President and Executive Director)
Lyu Yonghui (Co-Chief Executive Officer and Executive Director)
Heng Lei (Non-Executive Director)
Wang Lin (Non-Executive Director)
Huo Yunlong (Non-Executive Director)
Li Ho Man (Independent Non-Executive Director)
Liu Shuen Kong (Independent Non-Executive Director)
Chen Xuefeng (Independent Non-Executive Director)
Company Secretary Chu Cheuk Ting
Zhang Liang
Principal Bankers China Merchants Bank
China CITIC Bank Corporation Limited
Solicitors Campbells
Jingtian & Gongcheng
O Melveny & Myers LLP
Auditors Shinewing (HK) CPA Limited
Registered Office Room 19-108, 19th Floor, Cityplaza Three, 14 Taikoo Wan Road, Taikoo, Hong Kong
Share Registrars Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No (852) 2980-1333
Internet Address http://www.rainmed.com
Email Address [email protected]
Tel No (86 512) 6262-2215
Fax No (86 512) 6262-0120
 
SITEMAP
AASTOCKS.com
 
 
Members
 
About Us
Market
Quotes
 
Analysis
News & Research
 
Commentary
 
Warrants&CBBCs
 
Warrants
 
CBBCs
 
US Stocks
Forex
 
Fund
 
MPF
Email: [email protected]
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.